Article
Pharmacology & Pharmacy
Yuqian Wang, Sheng Li, Juan Bai, Xiaoxuan Cai, Shunli Tang, Peiyi Lin, Qingmiao Sun, Jianjun Qiao, Hong Fang
Summary: This study evaluated the efficacy and safety of bimekizumab in treating patients with psoriasis and determined the optimal maintenance dosing schedules. The results showed that bimekizumab had better efficacy than placebo or active comparators in treating psoriasis. After 16 weeks of initial maintenance treatment, both bimekizumab maintenance dosing schedules (320 mg every 4 and 8 weeks) had similar efficacy.
THERAPEUTIC ADVANCES IN CHRONIC DISEASE
(2023)
Review
Medicine, General & Internal
Klervi Golhen, Carolyn Winskill, Martin Theiler, Michael Buettcher, Yu-Hsin Yeh, Nancy Zhang, Tatjana Welzel, Marc Pfister
Summary: The study analyzed the efficacy and safety data of biologics in pediatric patients with moderate-to-severe psoriasis, finding that all biologics showed significantly improved efficacy compared to control groups and had low rates of serious adverse events.
FRONTIERS IN MEDICINE
(2022)
Article
Dermatology
Chunlei Zhang, Kexiang Yan, Qingchun Diao, Qing Guo, Hongzhong Jin, Sen Yang, Xiang Chen, Tiechi Lei, Jianhua Wu, Hong Yu, Min Zheng, Xinghua Gao, Rodney Sinclair, Yi Zhu, Qian Xu, Jinhua Xu
Summary: This study evaluated the efficacy and safety of Vunakizumab in patients with moderate-to-severe plaque psoriasis. The results showed that Vunakizumab groups had significantly higher proportions of patients with at least 75% improvement in the Psoriasis Area and Severity Index compared to the placebo group, with no unexpected adverse effects observed. However, the study had limitations such as a relatively short duration and lack of an active control group.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
(2022)
Review
Dermatology
Jessica E. Ferguson, Edward W. Seger, Jacob White, Amy McMichael
Summary: There may be differences in the efficacy of biologics based on race/ethnicity. The study suggests that there are variations in the effectiveness of biologic treatments for plaque psoriasis between different racial and ethnic groups.
ARCHIVES OF DERMATOLOGICAL RESEARCH
(2023)
Article
Medicine, General & Internal
Matteo Megna, Angelo Ruggiero, Teresa Battista, Laura Marano, Sara Cacciapuoti, Luca Potestio
Summary: This study investigated the long-term efficacy and safety of risankizumab for the management of moderate to severe psoriasis. The results showed significant reduction in psoriasis severity scores from week 16 and maintained up to week 104, with no serious adverse events reported.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Dermatology
Jensen Yeung, Marc Bourcier, Melinda J. Gooderham, Parbeer Grewal, Chih-Ho Hong, Perla Lansang, Charles Lynde, Catherine Maari, Vimal H. Prajapati, Irina Turchin, Ron Vender
Summary: A group of Canadian dermatologists convened to develop a consensus statement for treating moderate-to-severe plaque psoriasis using biologics. They proposed a multidimensional approach to defining treatment targets and a criterion-based system for determining treatment success.
DERMATOLOGIC THERAPY
(2022)
Article
Medicine, General & Internal
Kenneth B. Gordon, Peter Foley, James G. Krueger, Andreas Pinter, Kristian Reich, Ronald Vender, Veerle Vanvoorden, Cynthia Madden, Katy White, Christopher Cioffi, Andrew Blauvelt
Summary: The study demonstrated that Bimekizumab showed high levels of response in patients with moderate to severe plaque psoriasis, with durable effects over 56 weeks under both maintenance dosing schedules (every 4 weeks and every 8 weeks). Additionally, Bimekizumab was well tolerated with no unexpected safety issues, further supporting its therapeutic value for this patient population.
Article
Immunology
Saeideh Sadat Shobeiri, Motahareh Khorrami, Mojtaba Sankian
Summary: Psoriasis is a common inflammatory skin disorder mediated by the immune system, affecting 1-4% of the world's population. Treatments include topical therapy, phototherapy, systemic drugs, and advancing options like biological drugs, bispecific agents, and small molecule drugs to provide patients with more treatment choices.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2021)
Review
Dermatology
Yara E. Aljefri, Abdullah A. Ghaddaf, Tala A. Alkhunani, Taif A. Alkhamisi, Rana A. Alahmadi, Awadh M. Alamri, Ali A. Alraddadi
Summary: This study evaluated the efficacy and safety of apremilast monotherapy for moderate-to-severe plaque psoriasis. The results indicated that apremilast was more effective than placebo in achieving PASI-75, with higher rates of adverse events observed in the 30 mg BID group.
DERMATOLOGIC THERAPY
(2022)
Review
Rheumatology
Bruce W. Kirkham, Alexander Egeberg, Frank Behrens, Andreas Pinter, Joseph F. Merola, Thorsten Holzkaemper, Gaia Gallo, Khai Jing Ng, Rebecca Bolce, Christopher Schuster, Peter Nash, Luis Puig
Summary: For psoriatic arthritis (PsA) patients with nail psoriasis and patients with plaque psoriasis (PsO) with nail psoriasis, IXE treatment showed better improvement in resolving the disease and maintained the results up to week 24. IXE demonstrated efficacy in treating nail psoriasis in clinical trials and may be an effective therapy option.
RHEUMATOLOGY AND THERAPY
(2023)
Review
Dermatology
April Armstrong, Kyle Fahrbach, Craig Leonardi, Matthias Augustin, Binod Neupane, Paulina Kazmierska, Marissa Betts, Andreas Freitag, Sandeep Kiri, Vanessa Taieb, Mahmoud Slim, Natalie Nunez Gomez, Richard B. Warren
Summary: Bimekizumab, a selective inhibitor of both interleukin (IL)-17A and IL-17F, has shown superior efficacy compared to other biologic systemic therapies in achieving short-term improvement among patients with moderate to severe plaque psoriasis.
DERMATOLOGY AND THERAPY
(2022)
Article
Dermatology
R. Curmin, S. Guillo, Y. De Rycke, H. Bachelez, M. Beylot-Barry, N. Beneton, O. Chosidow, A. Dupuy, P. Joly, D. Jullien, M. A. Richard, M. Viguier, E. Sbidian, C. Paul, E. Mahe, F. Tubach
Summary: This study described the switching patterns of biologic treatments and showed how they changed over time, particularly with the availability of new biologic agents.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
(2022)
Review
Pharmacology & Pharmacy
Laura Calabrese, Dalma Malvaso, Flaminia Antonelli, Maria Mannino, Ketty Peris, Andrea Chiricozzi
Summary: This review aims to explore new therapeutic strategies and novel drugs currently in development for the treatment of psoriasis, primarily focusing on agents in phase I/II of clinical development. Some of these drugs build upon existing therapeutic approaches, such as inhibition of the IL23/Th17 pathway, while others introduce new and unexplored methods.
EXPERT OPINION ON INVESTIGATIONAL DRUGS
(2023)
Review
Dermatology
M. Augustin, M. Valencia Lopez, K. Reich
Summary: The study found a significant number of NMAs published in psoriasis showing highly comparable results in efficacy, but lacking sufficient information on quality criteria and not following standardized reporting guidelines.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
(2021)
Article
Medicine, General & Internal
Ran Pan, Xiaolun Wang, Min Shu, Jaydeep Das, Manik Kalra, Zhidong Wang
Summary: The efficacy of SEC in the treatment of patients with moderate-to-severe plaque psoriasis is well demonstrated through NMA.
CHINESE MEDICAL JOURNAL
(2022)